Providence and GRAIL Expand Partnership to Increase Access to Galleri Multi-Cancer Early Detection Screening

Providence, a not-for-profit health system serving the Western U.S., and GRAIL, LLC, a healthcare company with a mission to detect cancer early when it can be cured, announced the expansion of their partnership to offer multi-cancer early detection screening as part of clinical care to eligible individuals across the entire Providence health system.

Read More about AiThority Interview: AiThority Interview with Jon Zimmerman, Chief Executive Officer at Holon Solutions

“Providence is committed to collaborations that provide individuals with the best evidence-based care including advancements like early cancer screenings that can improve patient outcomes”

Through the partnership, eligible patients at Providence’s 52 hospitals and 900 clinics across seven states will have access to GRAIL’s Galleri^® multi-cancer early detection (MCED) test, as part of a comprehensive range of health services. In clinical studies, Galleri has demonstrated the ability to detect signals across more than 50 types of cancers — more than 45 of which lack recommended screening tests today. When a cancer signal is detected, Galleri can help ascertain where in the body the cancer is located with high accuracy, all from a single blood draw. In addition to broadening access to MCED testing, the expansion supports innovative diagnostics and genomics research aimed at improving cancer screening and treatment.

“Providence is committed to collaborations that provide individuals with the best evidence-based care including advancements like early cancer screenings that can improve patient outcomes,” said Ora Karp Gordon, M.D., Regional Medical Director of Providence’s Clinical Genetics & Genomics Program. “As a complement to current cancer screening programs, we believe the novel Galleri test offers an innovative way to assist with early cancer detection, especially with patients at high risk for difficult to detect cancers.”

AiThority Interview Insights: AiThority Interview with Kyle Wong, Chief Strategy Officer at Emplifi

According to the American Cancer Society, more than 609,000 people are expected to die from cancer in 2023 in the U.S. This is in large part because some of the deadliest cancers are identified in later stages when outcomes are often poorer. Though cancer screening tests can lead to life-saving treatments, only five types of tests are available in the U.S.: breast, colon, cervical, prostate, and, in high-risk adults, lung. In fact, about 71% of cancer deaths are a result of cancers that lack early detection screening.

“One of the best ways to improve cancer outcomes is to find cancer earlier, when it is easier to treat and the likelihood of survival is higher,” said Jeffrey Venstrom, M.D., Chief Medical Officer at GRAIL. “We are thrilled to expand our partnership with innovative health systems like Providence to promote broader adoption of our MCED blood test within their expansive network. Ultimately our goal is to reduce the burden of cancer and continue to advance understanding of the disease.”

Providence was the first health system in the nation to offer the MCED blood test as a complement to recommended cancer screenings to advance the science and delivery of cancer care. Providence and GRAIL previously announced an initial partnership in March 2021 to offer Galleri at Providence’s California, Washington and Oregon points of care. With the expanded partnership, Galleri is now available to eligible patients through Providence in Alaska, Montana, New Mexico and Texas.

 Latest AiThority Interview Insights : AiThority Interview with Malcolm Koh, Director, CX Practice at Zendesk

 [To share your insights with us, please write to sghosh@martechseries.com]